LAUSR

About LAUSR
Donate
Contact Us

Follow us:

You are not signed in:

Sign Up!


   Articles with "ras mutated" as a keyword



Autophagy inhibition specifically promotes epithelial-mesenchymal transition and invasion in RAS-mutated cancer cells

Sign Up to like & get
recommendations! Published in 2019 at "Autophagy"

DOI: 10.1080/15548627.2019.1569912

Abstract: ABSTRACT Macroautophagy/autophagy inhibition is a novel anticancer therapeutic strategy, especially for tumors driven by mutant RAS. Here, we demonstrate that autophagy inhibition in RAS-mutated cells induces epithelial-mesenchymal transition (EMT), which is associated with enhanced tumor… read more here.

Keywords: autophagy inhibition; mesenchymal transition; inhibition; epithelial mesenchymal ... See more keywords

Abstract B033: Wild-type RAS signaling is an essential therapeutic target in RAS-mutated cancers

Sign Up to like & get
recommendations! Published in 2023 at "Molecular Cancer Research"

DOI: 10.1158/1557-3125.ras23-b033

Abstract: Single-agent targeting of RAS-mutated cancers using RAF/MEK/ERK or PI3K/AKT pathway inhibitors is ineffective; blocking one pathway relieves negative feedback control of RTK signaling and hyperactivates parallel effector pathways. While combined MEK and PI3K inhibition is… read more here.

Keywords: mutated cancers; ras signaling; signaling essential; mutant ras ... See more keywords

Impact of NPM1 co-mutation on outcomes in RAS-mutated Acute Myeloid Leukemia

Sign Up to like & get
recommendations! Published in 2025 at "Blood"

DOI: 10.1182/blood-2025-7029

Abstract: Introduction: Oncogenic Mutations in RAS, most commonly involving NRAS and KRAS, occur in 10–25% of cases of acute myeloid leukemia (AML) and have been implicated in the disease biology of monocytic subtypes of AML. RAS… read more here.

Keywords: ras mutated; npm1 mutations; mut npm1; ras mut ... See more keywords

Preclinical Therapeutic Efficacy of RAF/MEK/ERK and IGF1R/AKT/mTOR Inhibition in Neuroblastoma

Sign Up to like & get
recommendations! Published in 2024 at "Cancers"

DOI: 10.3390/cancers16132320

Abstract: Simple Summary The prognosis for patients with relapsed neuroblastoma is poor, and novel treatment options for these patients are needed. Some relapsed neuroblastoma tumors harbor activating mutations in the RAS/MAPK pathway. In prior studies, single… read more here.

Keywords: igf1r; ras mutated; combination; trametinib ganitumab ... See more keywords